RSV (respiratory syncytial virus) is a common virus that can cause upper and lower respiratory tract infection, particularly in young infants and older adults. Symptoms range from mild cold-like symptoms to severe conditions such as bronchiolitis and pneumonia.
The virus is highly contagious and spreads through respiratory droplets when an infected person coughs or sneezes.
Pregnant women: a single dose of Abrysvo® is recommended for use in pregnant women at 28–36 weeks gestation to protect their newborn infant. This is provided free on the National Immunisation Program.
Older adults: a single dose of RSV vaccine (either Abrysvo® or Arexvy®) is recommended to protect all people aged ≥75 years, Aboriginal and Torres Strait Islander people aged ≥60 years, and people with medical risk factors for severe RSV disease aged ≥60 years. A private prescription is required.
Infants: a single dose of Beyfortus™ (nirsevimab) is recommended before their 1st RSV season in young infants whose mothers did not receive RSV vaccine at least 2 weeks before delivery, and in young infants who are at increased risk of severe RSV disease, regardless of their mother’s vaccination status.
Children up to 24 months of age who have medical risk factors for severe RSV disease in their 2nd RSV season. The dose of Beyfortus™ for older children entering their 2nd RSV season is 200 mg, given as 2 intramuscular injections (2 × 1 mL of the 100 mg/mL formulation) at 2 different sites (preferably separate limbs, or else separated by 2.5 cm) during the same visit.
Immunisation Weekly Update: Welcome to our weekly Immunisation Update! In this week’s update read about: GP alert: Abrysvo® vaccine administration errors Annual immunisation update 2025 – recording now available Measles alert – two confirmed cases Measles vaccine QI activity Beyfortus™ special order form GP alert – Abrysvo® vaccine administration errors…
Immunisation Weekly Update: Immunisation Weekly Update: RSV vaccine: Error alertFlu vaccination advice for 2025AIR infographicsArexvy® vaccine safety data Updated COVID-19 resourcesEducation RSV vaccine: Error alert The introduction of new vaccine products can increase the risk of vaccine administration errors. Immunisation providers must ensure that a vaccine is clinically appropriate for the…
Immunisation Weekly Update: Immunisation Weekly Update: Infant RSV immunisation program launches this weekBeyfortus™ (nirsevimab) dosage and administrationAuthority to administer RSV immunisation productsNIP influenza program advice and ATAGI statement 2025Flu vaccine pre-allocation orders close on FridayEducation Infant RSV immunisation program launches this week The National RSV Mother and Infant Protection Program…
Immunisation Weekly Update: Welcome to our weekly Immunisation Update! In this week’s update read about: Measles alert: Eastgardens, Botany, Alexandria, Sydney CBD and Darling Square Flu vaccine pre-allocation orders will close next week Mandatory AIR pregnancy status reporting starts next week Register for Pneumococcal Vaccination Recall QI Program in 2025…
Immunisation Weekly Update: Welcome to our weekly Immunisation Update! In this week’s update read about: Measles alert: Eastgardens, Botany, Alexandria, Sydney CBD and Darling Square Flu vaccine pre-allocation orders will close next week Mandatory AIR pregnancy status reporting starts next week Register for Pneumococcal Vaccination Recall QI Program in 2025…